

4DMEDICAL TO PRESENT AT NWR COMMUNICATIONS VIRTUAL INVESTOR CONFERENCE

17 March 2021: 4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”), a medical technology company focused on commercialising its patented respiratory imaging platform, is pleased to announce it will present at the NWR Virtual Investor Conference on Thursday 18 March 2021.

The Company invites shareholders and investors to see 4DMedical Managing Director & CEO Dr Andreas Fouras present an update at **11:20am AEDT** on 18 March 2021.

Event: NWR Communications Virtual Investor Conference
Presenting: Dr Andreas Fouras (Managing Director & CEO, 4DMedical)
Time: Thursday 18 March 2021, 11:20am AEDT for 30 minutes

Investors are **invited to submit questions** prior to the event to: simon@nwrcommunications.com.au.

Investors can register online to view the presentation here:
https://us02web.zoom.us/webinar/register/WN_boq80ZtNTISKVU5MJWZJhQ

For more information on the conference click here: <https://nwrconference.webflow.io/>

ENDS

Authorised on behalf of the 4DMedical Board of Directors by Andreas Fouras, CEO.

Contacts:

Corporate	Investor	Media
Charlene Stahr	Simon Hinsley	Matthew Wright
Company Secretary	+ 61 401 809 653	+ 61 451 896 420
companysecretary@4dmedical.com	shinsley@4dmedical.com	matt@nwrcommunications.com.au

About 4DMedical:

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical (formerly 4Dx) was founded in 2012 and is listed on the Australian Securities Exchange (ASX: 4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.